EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

Gian Paolo Fadini iD, Mario Luca Morieri, Carlotta Boscaro, Benedetta Maria Bonora, Andrea Cignarella

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6405-6412

DOI: 10.1111/dom.70840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.05.2026. Verfasst von Gian Paolo Fadini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Padova, Padua, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Semaglutide, Weight Loss. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Padova, University of Padova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Oral semaglutide absorption is subject to inter‐individual variability. We investigated whether estimated individual exposure ( eC avg ) provides predictive information beyond the prescribed dose in a real‐world cohort of patients with type 2 diabetes (T2D). Materials and Methods We retrospectively included patients initiating oral semaglutide to calculate eC avg at each follow‐up visit, using a validated population pharmacokinetic model incorporating dose, weight, sex, ethnicity and GI disorders, but without measuring plasma semaglutide concentrations. Mixed‐effects models were used to assess the associations of dose and eC avg with changes in HbA1c and percent body weight, and to compare model fit. For GI side effects, time‐adjusted fixed‐effects logistic regression was employed.

Results

We analysed 256 participants (31.6% women, mean age 65.6 years). During a median follow‐up of 19 months, HbA1c declined by 0.7% and body weight by 7.5%; 41.8% of patients reported GI side effects. Both dose and eC avg were significantly associated with all outcomes when analysed individually. For ΔHbA1c, the dose model outperformed the eC avg model ( p < 0.01), while eC avg showed modestly improved fit for weight loss ( p < 0.001). The exposure‐effect relationship was clearly right‐shifted for weight loss compared to the glycaemic effect. For GI side effects, eC avg remained significantly associated with the outcome after adjustment for dose residuals, indicating that eC avg had greater predictive value for tolerability.

Conclusions

Although estimated and not measured, the exposure to oral semaglutide may provide outcome‐dependent information. While the prescribed dose seems sufficient to predict glycaemic response, estimated exposure provides additional value for weight loss and GI tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsSemaglutideWeight LossGlucagon-Like Peptide-1 Receptor AgonistsAgedFemaleHumansMaleMiddle AgedAdministration, OralBlood GlucoseDose-Response Relationship, DrugGastrointestinal DiseasesGlycated HemoglobinRetrospective Studies

Stichwörter der Autor:innen

pharmacokineticsreal‐world evidencesemaglutidetype 2 diabetes

Substanzen

Blood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Medicine, University of Padova, Padua, Italy.
  • Veneto Institute of Molecular Medicine, Padua, Italy.

ORCID-Profile: Gian Paolo Fadini

Förderung

  • Università degli Studi di Padova
  • University of Padova

Zitieren

APA

Fadini, G. P., Morieri, M. L., Boscaro, C., Bonora, B. M., & Cignarella, A. (2026). Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability. Diabetes, Obesity and Metabolism, 28(7), 6405-6412. https://doi.org/10.1111/dom.70840

Vancouver

Fadini GP, Morieri ML, Boscaro C, Bonora BM, Cignarella A. Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability. Diabetes, Obesity and Metabolism. 2026;28(7):6405-6412. doi:10.1111/dom.70840

BibTeX
@article{Fadini2026,
  author = {Fadini, Gian Paolo and Morieri, Mario Luca and Boscaro, Carlotta and Bonora, Benedetta Maria and Cignarella, Andrea},
  title = {Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {6405--6412},
  doi = {10.1111/dom.70840}
}
Kostenlos starten →